Champignon Closes AltMed Transaction, Partners With Leading Canadian Pharmacy

Champignon Brands (CSE: SHRM) today announced that it has partnered with a major pharmacy chain within Canada to dispense its ketamine topical prescription product throughout the network. While the pharmacy chain was not addressed by name, it is said to be one of the leading chains within the country.

Under the arrangement, Champignon will see the pharmacy perform central fill and compounding functions for the firms proprietary ketamine formulations at one location. The products will then be distributed as needed throughout the pharmacies network of locations. Champignon will be utilizing this network to also distribute its products to numerous medical and pain and addiction clinics throughout the nation.

In connection with the arrangement, Champignon and the pharmacy have begun to design a custom level “B” clean room which will be used to compound and package the ketamine formulations, which is expected to be completed by the third quarter of 2020. Such formulations include off-market intranasal esketamine and ketamine topicals.

“With this arrangement, Champignon boasts complete vertical integration with respect to our rapid onset ketamine treatments and therapies. From novel formulations to product development at a purpose-built GMP and DIN licensed pharmaceutical facility, and now automated prescription fulfillment and on-site compounding infrastructure, we have managed to capture the entire product lifecycle.”
Gareth Bridsall, CEO

Outside the developments of Champignon’s ketamine formulations, the company also announced that it has closed the transaction with that of AltMed Capital Corp. AltMed operates a ketamine clinic in Ontario known as the Canadian Rapid Treatment Centre of Excellence (CRTCE), for which it recently acquired 100% of, in addition to being a psychedelic medicine IP aggregator and novel drug discoverer.

Champignon currently intends to open five additional ketamine clinics across North America by the fourth quarter of 2020, with locations planned for New York, California, and Florida.

Champignon Brands last traded at $0.88 on the CSE.


FULL DISCLOSURE: Champignon Brands is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Champignon Brands on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

Video Articles

IAMGOLD Q3 Earnings: Market Responds With MASSIVE Price Lift

G Mining Q3 Earnings: Costs Down, Production Up

Endeavour Silver Q3 Earnings: On The Upswing

Recommended

Silver47 Hits 606 g/t Over 9.7 Metres Silver Equivalent In Final Assays From 2025 Drill Program At Red Mountain

Altamira Gold Encounters Second Porphyry Body, Hitting 3.5 g/t Gold Over 8.0 Metres

Related News

Champignon Brands To Acquire Psilocybin Research Firm Tassili Life Sciences

Last night, Champignon Brands (CSE: SHRM) announced that they have signed a definitive agreement to...

Saturday, March 28, 2020, 01:12:34 PM

Shroom Rush? Champignon Announces $10M Bought Deal

This afternoon Champignon Brands Inc. (CSE: SHRM) announced they entered into an agreement on a...

Monday, May 11, 2020, 05:03:14 PM

Market Movers: Champignon Brands Tags $2; Up Over 35%

This morning Champignon Brands (CSE: SHRM) continued to gain momentum as the stock increased to...

Friday, May 15, 2020, 11:39:20 AM

Champignon Brands To Acquire Biotech Firm Novo Formulations

Champignon Brands (CSE: SHRM) announced today that they have signed a definitive agreement to acquire...

Thursday, March 19, 2020, 03:27:32 PM

Harvest Moon: Reducing Suicidal Ideation With Ketamine Infusions

Suicidal ideation is an emergent condition that demands immediate attention. It has been shown that...

Tuesday, May 26, 2020, 03:00:00 PM